Gilles Divita PhD

Dr. Gilles Divita is a co-founder and CEO of DivinCell SAS (FR) and Chief Scientist at Aadigen LLC, California (USA), a BioPharmaceutical NanoMedicine Start-up pioneering novel RNA therapeutic drug delivery for the treatment of cancer and genetic diseases. Dr. DIVITA has over 25 years of experience in drug delivery systems, peptide drugs, and oligonucleotide therapeutics. Dr Divita’s work focuses on strategies to probe and perturb the behavior of biomolecules in physiological and pathological settings. He is the pioneer of the “non-covalent cell penetrating peptide-based strategy” for therapeutic delivery and inventor of the peptide-based platform that is used by Aadigen and Divincell for its RNA therapeutic strategy.

Dr. DIVITA is the author of over 200 articles in peer-reviewed scientific journals and of 25 patents. Dr. DIVITA holds a Ph.D. in Biochemistry/Biophysics from the University of Lyon, France. He worked as a Scientist at the Max Planck Institute for Medical Research in Heidelberg, Germany, and then as an Associate Professor at the SCRIPPS Research Institute, La Jolla, USA.  In 1996, Dr. DIVITA joined the French National Center for Scientific Research (CNRS) and was Research Director, Head of Chemical Biology and Nanotechnology for the Therapeutics Team at the CNRS in Montpellier, France, from 1999 to 2016. In 2018, He cofounded Divincell with Neil Desai.